VIA
CLDX icon

Vident Investment Advisory’s Celldex Therapeutics CLDX Stock Holding History

Vident Investment Advisory’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-39,134
Closed -$477K – 915
2018
Q1 		$477K Buy
39,134
+10,629
+37% +$412K 0.02% 628
2017
Q4 		$1.21M Sell
28,505
-4,496
-14% -$193K 0.05% 350
2017
Q3 		$1.42M Buy
33,001
+1,000
+3% +$37.5K 0.08% 321
2017
Q2 		$1.19M Buy
32,001
+16,264
+103% +$719K 0.1% 304
2017
Q1 		$852K Buy
15,737
+2,623
+20% +$137K 0.08% 318
2016
Q4 		$696K Buy
13,114
+2,875
+28% +$164K 0.08% 313
2016
Q3 		$620K Buy
10,239
+196
+2% +$12.2K 0.08% 321
2016
Q2 		$661K Buy
10,043
+3,863
+63% +$245K 0.09% 337
2016
Q1 		$350K Buy
6,180
+2,884
+88% +$324K 0.02% 367
2015
Q4 		$775K Buy
+3,296
New +$719K 0.1% 336

Other funds holding CLDX

KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vident Investment Advisory's CLDX Position: Q2 2018 in Review

Vident Investment Advisory sold out of Celldex Therapeutics (CLDX) in Q2 2018, closing a stake of 39,134 shares — an estimated $477K sold.

Vident Investment Advisory first reported a position in CLDX in Q4 2015 and held it in 10 quarters. The position peaked at $1.42M in Q3 2017. 102 funds tracked by Wall St. Rank hold CLDX as of Q2 2018.

  • Vident Investment Advisory reported no remaining Celldex Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Vident Investment Advisory sold 39,134 Celldex Therapeutics shares in Q2 2018, an estimated $477K.
  • Vident Investment Advisory first reported a position in Celldex Therapeutics in Q4 2015 and held it in 10 quarters.
  • Vident Investment Advisory's Celldex Therapeutics position peaked at $1.42M in Q3 2017.
  • 102 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2018.

Based on Vident Investment Advisory's 13F filing for Q2 2018, filed 14 Aug 2018.